The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

Epirubicinol     7-(4-amino-6-methyl-oxan-2- yl)oxy-9-(1,2...

Synonyms: AC1L2USK, AR-1G5782, AC1Q6JJ3, A845310, 4-DOL, ...
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of Epirubicinol

 

High impact information on Epirubicinol

 

Associations of Epirubicinol with other chemical compounds

 

Analytical, diagnostic and therapeutic context of Epirubicinol

  • Defective taxane stimulation of epirubicinol formation in the human heart: insight into the cardiac tolerability of epirubicin-taxane chemotherapies [5].

References

  1. Gemcitabine, epirubicin and paclitaxel: pharmacokinetic and pharmacodynamic interactions in advanced breast cancer. Fogli, S., Danesi, R., Gennari, A., Donati, S., Conte, P.F., Del Tacca, M. Ann. Oncol. (2002) [Pubmed]
  2. Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients. Danesi, R., Innocenti, F., Fogli, S., Gennari, A., Baldini, E., Di Paolo, A., Salvadori, B., Bocci, G., Conte, P.F., Del Tacca, M. British journal of clinical pharmacology. (2002) [Pubmed]
  3. Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients. Esposito, M., Venturini, M., Vannozzi, M.O., Tolino, G., Lunardi, G., Garrone, O., Angiolini, C., Viale, M., Bergaglio, M., Del Mastro, L., Rosso, R. J. Clin. Oncol. (1999) [Pubmed]
  4. Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans. Mross, K., Maessen, P., van der Vijgh, W.J., Gall, H., Boven, E., Pinedo, H.M. J. Clin. Oncol. (1988) [Pubmed]
  5. Defective taxane stimulation of epirubicinol formation in the human heart: insight into the cardiac tolerability of epirubicin-taxane chemotherapies. Salvatorelli, E., Menna, P., Gianni, L., Minotti, G. J. Pharmacol. Exp. Ther. (2007) [Pubmed]
  6. A phase I and pharmacokinetic study of paclitaxel and epirubicin in advanced cancer. Rischin, D., Webster, L.K., Millward, M.J., Toner, G.C., Nawaratne, S., Ganju, V., Francis, P., Bishop, J.F. Investigational new drugs. (1999) [Pubmed]
  7. Different cytotoxicity and metabolism of doxorubicin, daunorubicin, epirubicin, esorubicin and idarubicin in cultured human and rat hepatocytes. Le Bot, M.A., Bégué, J.M., Kernaleguen, D., Robert, J., Ratanasavanh, D., Airiau, J., Riché, C., Guillouzo, A. Biochem. Pharmacol. (1988) [Pubmed]
  8. Occurrence of circulating 7-deoxyaglycone metabolites of 4'-deoxydoxorubicin in man. Cummings, J., Kerr, D.J., Kaye, S.B. Cancer Chemother. Pharmacol. (1987) [Pubmed]
  9. Determination of plasma concentrations of epirubicin and its metabolites by high-performance liquid chromatography during a 96-h infusion in cancer chemotherapy. Barker, I.K., Crawford, S.M., Fell, A.F. J. Chromatogr. B, Biomed. Appl. (1996) [Pubmed]
 
WikiGenes - Universities